In a sunlit lab at the University of Vienna, Ph.D. student Uroš Vezonik stirred a flask containing a simple mixture—no exotic catalysts, no inert atmosphere—just an amine, an alkene, and formaldehyde. Within hours, a transformation occurred that once would have taken weeks: a methyl group on a drug-like molecule vanished and was replaced by a complex fragment, like a sentence rewritten with surgical precision. This is the heart of a breakthrough from Nuno Maulide’s team—a one-step 'alkyl swap' that could redefine how chemists build medicines.
For over a century, organic synthesis has been a meticulous craft: constructing molecules bond by bond, often requiring dozens of steps to tweak a single functional group. Now, Maulide’s group has introduced a method that bypasses that labor, directly modifying N-methylamines—structures so ubiquitous they form the backbone of neurotransmitters, proteins, and 70% of top-selling pharmaceuticals. The ability to edit these molecules selectively, without dismantling them, opens a new frontier in drug discovery.
The team’s approach, published in Nature Chemistry, leverages simple alkenes—common hydrocarbons—to swap out the methyl group (CH₃) of secondary amines and replace it with far more complex alkyl chains. In one experiment, they transformed derivatives of fluoxetine, duloxetine, sertraline, atomoxetine, and citalopram—medications used to treat depression and ADHD—with pinpoint accuracy. Even more striking, they synthesized several commercially relevant drugs in just a single reaction step, a feat that typically demands multi-step routes with protective groups and harsh conditions.
What sets this method apart is its astonishing simplicity. Dubbed 'bathtub chemistry' by Maulide, the reaction proceeds under mild, open-air conditions, requiring no oxygen-free glovebox or expensive metal catalysts. "You can modify highly complex molecules at a very specific point without touching the rest of the molecule," says Daniel Kaiser, co-author. That robustness allowed the team to functionalize peptides and create peptide-drug conjugates—molecules of growing importance in targeted cancer therapies—something previously unattainable with conventional methods.
The implications for drug development are profound. Pharmaceutical researchers often screen hundreds of molecular variants to optimize efficacy and safety. With this alkyl swap, entire libraries of modified drug candidates can be generated rapidly from a single parent compound. Giulia Iannelli, co-first author, emphasizes: "This allows us to functionalize complex amines that could not be transformed in this way with any other known method."
Beyond its immediate utility, the work represents a shift in chemical thinking. By using stable, abundant alkenes instead of reactive aldehydes and reducing agents, the method reimagines the logic of synthesis. Molecules once considered out of reach are now within grasp. As Maulide puts it, "Suddenly, molecules that were previously extremely difficult to synthesize become much more accessible." In a field where progress often hinges on incremental advances, this leap feels like a quiet revolution—one that might one day help turn simple flasks into faster paths to life-saving drugs.